Skip to content

Intelligence report 01

Protocol and Eligibility Assessment

How inclusion and exclusion criteria shape the eligible population, and where the protocol adds recruitment risk.

Format
Written report and walkthrough
Available for
Neurodegenerative diseases, Type 1 diabetes
Evidence
Every figure sourced and graded A to D

About this sample. This page shows the method and structure of the report. It contains no client data; every engagement is prepared for the specific study and indication.

1Overview

A structured review of the inclusion and exclusion criteria of a planned study. Each criterion is translated into measurable population terms and applied in sequence to an epidemiological base population, so the effect of every criterion on the eligible pool is visible and traceable.

2Questions this report answers

  • ?How many patients are likely to meet the core eligibility criteria?
  • ?Which individual criteria remove the largest share of the population?
  • ?Are any criteria inconsistent with how the disease is diagnosed and recorded in practice?
  • ?How do the criteria compare with recent registered trials in the same indication?

3Protocol

The report follows the same documented sequence for every study. Each step produces an output that is kept in the final report.

  1. 1

    Protocol intake

    The synopsis or draft protocol is reviewed and every inclusion and exclusion criterion, endpoint and key visit requirement is listed in a criteria inventory.

    Output: Criteria inventory

  2. 2

    Criteria mapping

    Each criterion is expressed in measurable terms such as age range, diagnosis, disease stage, laboratory thresholds or prior therapy, with the data source that can measure it.

    Output: Mapped criteria table

  3. 3

    Population sizing

    Starting from the epidemiological base population, criteria are applied one at a time. The source, date and evidence grade of every step are recorded.

    Output: Eligibility funnel

  4. 4

    Benchmarking

    The criteria are compared with registered trials in the same indication and phase to identify restrictions that are unusual or stricter than common practice.

    Output: Benchmark table

  5. 5

    Risk review

    Criteria with the largest effect, ambiguous wording or measurement difficulty are assessed, together with endpoint and analysis considerations.

    Output: Risk register

  6. 6

    Report and walkthrough

    Findings are summarised with clear recommendations and reviewed with your team in a working session.

    Output: Report and session

4Report contents

SectionTitle
1Executive summaryKey findings and the criteria with the greatest effect on the eligible pool.
2Criteria inventoryEvery criterion, how it is measured and the data used.
3Eligibility funnelPopulation remaining after each criterion, with evidence grades.
4Comparable trialsHow the criteria compare with registered studies in the indication.
5Risk registerRecruitment and analysis risks, each with a recommendation.
6Assumptions appendixAll sources, dates and assumptions behind the figures.

5Evidence standards

Every figure in the report carries its source, its date and one of four evidence grades, so you can see what is confirmed and what is assumed.

A

Confirmed

Reported directly by an authoritative source.

B

Documented

Published or documented, with a clear method.

C

Estimated

Derived by Clinovia from graded inputs.

D

Assumed

An explicit assumption, open to review.

6Inputs and deliverables

What we need from you

  • Protocol synopsis or draft protocol
  • Target countries or regions
  • Planned or possible amendments, if any

What you receive

  • Written report (PDF)
  • Funnel and benchmark tables (Excel)
  • Walkthrough session with your team

Discuss this report for your study

Tell us about the indication and the decision in front of you. A pilot on a single study is a good place to start.

Other intelligence reports